Robert Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin, Steven M Horwitz, Brandon S Imber, Andrew M Intlekofer, William T Johnson, Niloufer Khan, Anita Kumar, Oscar B Lahoud, Jennifer Kimberly Lue, Matthew J Matasar, Alison J Moskowitz, Ariela Noy, Colette N Owens, M Lia Palomba, Heiko Schöder, Santosha A Vardhana, Joachim Yahalom, Andrew D Zelenetz, Gilles Salles, David J Straus
Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinical outcomes of patients with NMZL, we reviewed a sequential cohort of 187 patients with NMZL to describe baseline characteristics, survival outcomes, and time-to-event data. Initial management strategies were classified into five categories: observation, radiation, anti-CD20 monoclonal antibody therapy, chemoimmunotherapy, or other...
September 12, 2023: Blood Advances